Ardelyx Company Profile (NASDAQ:ARDX)

About Ardelyx (NASDAQ:ARDX)

Ardelyx logoArdelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARDX
  • CUSIP: N/A
  • Web:
  • Market Cap: $251.46 million
  • Outstanding Shares: 47,445,000
Average Prices:
  • 50 Day Moving Avg: $5.08
  • 200 Day Moving Avg: $7.94
  • 52 Week Range: $4.05 - $16.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.48
  • P/E Growth: -0.08
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.06 per share
  • Price / Book: 1.73
  • EBIDTA: ($113,620,000.00)
  • Return on Equity: -62.60%
  • Return on Assets: -56.57%
  • Current Ratio: 8.38%
  • Quick Ratio: 8.38%
  • Average Volume: 284,714 shs.
  • Beta: 0.18
  • Short Ratio: 5.1

Frequently Asked Questions for Ardelyx (NASDAQ:ARDX)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.09. View Ardelyx's Earnings History.

When will Ardelyx make its next earnings announcement?

Ardelyx is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Ardelyx.

Where is Ardelyx's stock going? Where will Ardelyx's stock price be in 2017?

5 equities research analysts have issued 12-month target prices for Ardelyx's stock. Their predictions range from $12.00 to $24.00. On average, they expect Ardelyx's share price to reach $15.60 in the next year. View Analyst Ratings for Ardelyx.

What are analysts saying about Ardelyx stock?

Here are some recent quotes from research analysts about Ardelyx stock:

  • 1. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (7/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)

Who are some of Ardelyx's key competitors?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board
  • Michael G. Raab, President, Chief Executive Officer, Director
  • Mark E. Kaufmann, Chief Financial Officer
  • Reginal Seeto, Chief Operating Officer, Executive Vice President
  • Jeremy S. Caldwell Ph.D., Executive Vice President, Chief Scientific Officer
  • Paul Korner M.D., Executive Vice President, Chief Medical Officer
  • Elizabeth Grammer Esq., Senior Vice President, General Counsel
  • David P. Rosenbaum Ph.D., Chief Development Officer
  • Robert B. Bazemore Jr., Independent Director
  • William C. Bertrand Jr. Esq., Independent Director

Who owns Ardelyx stock?

Ardelyx's stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (29.72%), FLYNN JAMES E (5.79%), FMR LLC (5.40%), Vanguard Group Inc. (2.70%), Marshall Wace North America L.P. (1.70%) and Tekla Capital Management LLC (1.35%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell and Nea 15 Gp, Llc. View Institutional Ownership Trends for Ardelyx.

Who sold Ardelyx stock? Who is selling Ardelyx stock?

Ardelyx's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, TD Asset Management Inc., TIAA CREF Investment Management LLC, California State Teachers Retirement System, ProShare Advisors LLC, Bank of New York Mellon Corp and New York State Common Retirement Fund. Company insiders that have sold Ardelyx stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs and Jeremy S Caldwell. View Insider Buying and Selling for Ardelyx.

Who bought Ardelyx stock? Who is buying Ardelyx stock?

Ardelyx's stock was bought by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., Dimensional Fund Advisors LP, DAFNA Capital Management LLC, Trexquant Investment LP, Citadel Advisors LLC, Vanguard Group Inc., Alliancebernstein L.P. and IndexIQ Advisors LLC. Company insiders that have bought Ardelyx stock in the last two years include Gordon Ringold and Nea 15 Gp, Llc. View Insider Buying and Selling for Ardelyx.

How do I buy Ardelyx stock?

Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of Ardelyx stock can currently be purchased for approximately $5.30.

MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ardelyx (NASDAQ:ARDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.60 (194.34% upside)

Analysts' Ratings History for Ardelyx (NASDAQ:ARDX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/28/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
5/23/2017BTIG ResearchLower Price TargetBuy$18.00 -> $12.00HighView Rating Details
5/15/2017Citigroup Inc.Reiterated RatingBuy$17.00 -> $12.00MediumView Rating Details
2/15/2017WedbushReiterated RatingOutperform$24.00N/AView Rating Details
11/20/2016Leerink SwannSet Price TargetBuy$18.00N/AView Rating Details
3/31/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$21.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for Ardelyx (NASDAQ:ARDX)
Earnings by Quarter for Ardelyx (NASDAQ:ARDX)
Earnings History by Quarter for Ardelyx (NASDAQ ARDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.54)N/AView Earnings Details
8/9/2017Q2 2017($0.63)($0.54)ViewListenView Earnings Details
5/5/2017Q1 2017($0.65)($0.59)ViewN/AView Earnings Details
2/17/2017Q4 2016($0.66)($0.66)ViewN/AView Earnings Details
11/7/2016Q316($0.74)($0.65)ViewListenView Earnings Details
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.02)($0.19)$9.65 million$5.88 millionViewN/AView Earnings Details
2/25/2015Q4 2014($0.06)($0.21)$8.15 million$6.34 millionViewListenView Earnings Details
8/7/2014Q2 2014$1.83$0.44$8.10 million$9.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ardelyx (NASDAQ:ARDX)
2017 EPS Consensus Estimate: ($2.35)
2018 EPS Consensus Estimate: ($1.99)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.56)($0.56)($0.56)
Q4 20172($0.56)($0.45)($0.51)
Q1 20181($0.48)($0.48)($0.48)
Q2 20181($0.50)($0.50)($0.50)
Q3 20181($0.53)($0.53)($0.53)
Q4 20181($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)


Dividend History for Ardelyx (NASDAQ:ARDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ardelyx (NASDAQ:ARDX)
Insider Ownership Percentage: 15.46%
Institutional Ownership Percentage: 78.58%
Insider Trades by Quarter for Ardelyx (NASDAQ:ARDX)
Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)
Insider Trades by Quarter for Ardelyx (NASDAQ:ARDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/30/2017Forest BaskettMajor ShareholderSell485$4.95$2,400.75View SEC Filing  
4/18/2017David P. RosenbaumInsiderSell2,051$11.98$24,570.98View SEC Filing  
3/3/2017Jeremy S. CaldwellEVPSell1,026$14.14$14,507.64View SEC Filing  
12/16/2016David P RosenbaumSVPSell900$14.48$13,032.00View SEC Filing  
10/11/2016Jeffrey W. JacobsSVPSell6,000$15.00$90,000.00View SEC Filing  
9/23/2016Elizabeth A GrammerSVPSell5,000$12.00$60,000.00View SEC Filing  
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.00View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.00View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.00View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.40View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.00View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.65View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.86View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ardelyx (NASDAQ:ARDX)
Latest Headlines for Ardelyx (NASDAQ:ARDX)
DateHeadline logoFinancial Survey: Ardelyx (ARDX) versus The Competition - September 18 at 4:31 PM logo Brokerages Anticipate Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per Share - September 9 at 10:22 AM logoArdelyx, Inc. (ARDX) Downgraded by ValuEngine to "Strong Sell" - September 3 at 10:10 PM logoArdelyx, Inc. (ARDX) Receives Average Recommendation of "Buy" from Brokerages - September 2 at 9:08 AM logoArdelyx, Inc. (ARDX) Upgraded at BidaskClub - August 28 at 11:50 PM logoArdelyx, Inc. (ARDX) Earns Buy Rating from Cantor Fitzgerald - August 28 at 10:16 AM logoEquities Analysts Set Expectations for Ardelyx, Inc.'s Q3 2017 Earnings (NASDAQ:ARDX) - August 14 at 3:36 AM logoArdelyx, Inc. Forecasted to Post Q1 2018 Earnings of ($0.48) Per Share (NASDAQ:ARDX) - August 11 at 2:14 PM logoEdited Transcript of ARDX earnings conference call or presentation 9-Aug-17 12:00pm GMT - August 10 at 5:26 PM logoArdelyx, Inc. (ARDX) Releases Earnings Results, Beats Expectations By $0.09 EPS - August 10 at 3:42 PM logoInvestor Network: Ardelyx, Inc. to Host Earnings Call - August 9 at 4:09 PM logoArdelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results - August 9 at 4:09 PM logoArdelyx reports 2Q loss - August 9 at 4:09 PM logoArdelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Buy" from Analysts - August 8 at 8:50 AM logoArdelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference - August 2 at 4:49 PM logoArdelyx, Inc. (NASDAQ:ARDX) Set to Announce Earnings on Monday - July 31 at 8:16 AM logoArdelyx, Inc. (NASDAQ:ARDX) Downgraded to "Hold" at Zacks Investment Research - July 18 at 4:56 PM logoArdelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from Brokerages - July 14 at 1:32 PM logoCatalyst (CPRX) Shows Strength: Stock Adds 9.6% in Session - July 12 at 4:29 PM logoArdelyx, Inc. (ARDX) Expected to Post Earnings of -$0.63 Per Share - July 12 at 8:30 AM featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant - July 10 at 3:58 PM logoArdelyx, Inc. (ARDX) Upgraded by ValuEngine to Sell - July 9 at 12:40 AM logo5 Breakout Stocks Offering Phenomenal Returns - July 8 at 6:22 AM logoArdelyx, Inc. (ARDX) Short Interest Up 31.5% in June - June 30 at 7:14 AM logoArdelyx, Inc. (ARDX) Receives Consensus Recommendation of "Buy" from Brokerages - June 19 at 8:34 AM logoArdelyx, Inc. (ARDX) Downgraded by ValuEngine to Strong Sell - June 13 at 12:28 AM logoArdelyx Inc (ARDX) Rating Reiterated by Cantor Fitzgerald - May 31 at 7:36 AM logoWith Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory? - May 29 at 3:58 PM logoArdelyx Inc (ARDX) Given New $12.00 Price Target at BTIG Research - May 27 at 11:16 PM logoZacks Investment Research Upgrades Ardelyx Inc (ARDX) to Buy - May 23 at 4:24 PM logoArdelyx Inc (ARDX) Receives Consensus Recommendation of "Buy" from Analysts - May 23 at 8:36 AM logoArdelyx Inc (ARDX) Forecasted to Post FY2017 Earnings of ($2.84) Per Share - May 22 at 7:22 AM logo-$0.63 Earnings Per Share Expected for Ardelyx Inc (ARDX) This Quarter - May 19 at 1:20 PM logoArdelyx Inc (ARDX) Earns "Overweight" Rating from Cantor Fitzgerald - May 19 at 10:52 AM logoArdelyx Inc (ARDX) Given "Buy" Rating at Citigroup Inc - May 15 at 3:50 PM logoShort Interest in Ardelyx Inc (ARDX) Decreases By 10.7% - May 15 at 8:48 AM logoAZN's PACIFIC Proves To Have Depth, ARDX Abuzz, No Flashy Data From ALLSTAR - May 14 at 3:42 PM logoArdelyx (ARDX) Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C Meets Primary Endpoint - May 12 at 9:13 PM logoArdelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C - May 12 at 4:11 PM logoArdelyx Inc (ARDX) Raised to Hold at Zacks Investment Research - May 11 at 10:52 PM logoWedbush Analysts Boost Earnings Estimates for Ardelyx Inc (ARDX) - May 11 at 9:16 AM logoArdelyx Inc (ARDX) Announces Quarterly Earnings Results - May 8 at 3:36 PM logoArdelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress - May 5 at 3:38 PM logoArdelyx reports 1Q loss - May 5 at 3:38 PM logoSomewhat Critical Press Coverage Somewhat Likely to Impact Ardelyx (ARDX) Share Price - May 2 at 5:28 PM logo Analysts Anticipate Ardelyx Inc (ARDX) to Announce -$0.61 Earnings Per Share - April 28 at 11:36 AM logoArdelyx (ARDX) Getting Favorable News Coverage, Report Shows - April 28 at 10:24 AM logoArdelyx Inc (ARDX) Downgraded by Zacks Investment Research - April 25 at 6:16 PM logoSomewhat Negative Media Coverage Somewhat Likely to Affect Ardelyx (ARDX) Share Price - April 25 at 1:08 PM logoArdelyx (ARDX) Receives Daily News Impact Rating of -0.12 - April 22 at 10:22 AM



Ardelyx (ARDX) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff